Targeted disruption of the K-Ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis

British Journal of Cancer

Volumn 80, Issue 12, 1999, Pages 1884-1891

  Allgayer, H ^a,c   Wang, H ^a   Shirasawa, S ^b   Sasazuki, T ^b   Boyd, D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KYUSHU UNIVERSITY   (Japan)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Colon cancer; K Ras; Knockout; Proteolysis; u PAR

Indexed keywords

LAMININ; PHORBOL ESTER; PLASMINOGEN; PROTEIN C FOS; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; UROKINASE RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; ELECTROPHORETIC MOBILITY; GENE ACTIVATION; GENE DISRUPTION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; ONCOGENE K RAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RECEPTOR GENE;

CELL NUCLEUS; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GENES, REPORTER; HUMANS; LAMININ; MUTAGENESIS; PLASMINOGEN; PROTEIN BIOSYNTHESIS; RECEPTORS, CELL SURFACE; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032778698     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690616     Document Type: Article

References (59)

1. Adler V, Unlap T and Kraft AS (1994) A peptide encoding the c-Jun δ domain inhibits the activity of a c-Jun amino-terminal protein kinase. J Biol Chem 269: 11186-11191
2. Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA, Stemmerman G, Wells JD, MacDonald JS and Meyskens FL (1998) Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a southwest oncology group study. Cancer Res 58: 1149-1158
3. Allgayer H, Heiss MM, Riesenberg R, Grutzner KU, Tarabichi A, Babic R and Schildberg FW (1997) Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res 57: 1394-1399
4. Allgayer H, Wang H, Wang Y, Heiss MM, Bauer R, Nyormoi O and Boyd D (1999) Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator protein-2α-related factor. J Biol Chem 274: 4702-1714
5. Behrendt N, Ploug M, Patthy L, Houen G, Blasi F and Dano K (1991) The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem 266: 7842-7847
6. Bohuslav J, Horejsi V, Hansmann C, Stoekl J, Weidle UH, Majdic O, Bartke I, Knapp W and Stockinger H (1995) Urokinase plasminogen activator receptor, B2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med 181: 1381-1390
7. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689
8. Boyd D, Florent G, Kim P and Brattain MG (1988) Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res 48: 3112-3116
9. Buard A, Zipfel PA, Frey RS and Mulder KM (1996) Maintenance of growth factor signalling through Ras in human colon carcinoma cells containing K-ras mutations. Int J Cancer 67: 539-546
10. Burnette W (1981) "Western Blotting" Electrophoretic transfer of proteins from sodium dodecyl sulfate polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Analyt Biochem 112: 195-203
11. Casey JR, Petranka JG, Kottra J, Fleenor DE and Rosse WF (1994) The structure of the urokinase-type plasminogen activator receptor gene. Blood 84: 1151-1156
12. 2-macroglobulin receptor. J Biol Chem 269: 17886-17892
13. Cubellis M, Wun T and Blasi F (1990) Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. Eur Mol Biol Organ 9: 1079-1085
14. Ellis V, Behrendt N and Dano K (1991) Plasminogen activation by receptor-bound urokinase. J Biol Chem 266: 12,752-12,758
15. Ganesh S, Sier CFM, Heerding MM, Griffioen G, Lamers CBH and Verspaget HW (1994) Urokinase receptor and colorectal cancer survival. Lancet 344: 401-402
16. lcf by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature 358: 414-417
17. Gum R, Juarez J, Allgayer H, Mazar A, Wang Y and Boyd D (1998) Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNKI-dependent and -independent signaling modules. Oncogene 17: 213-226
18. Herrera-Velit P, Knutson KL and Reiner NE (1997) Phosphatidylinositol 3-kinase-dependent activation of protein kinase C-zeta in bacterial lipopolylsaccharide-treated human monocytes. J Biol Chem 272: 16445-16452
19. Hibi M, Lin A, Minden A and Karin M (1993) Identification of an oncoprotein- and uv-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 7: 2135-2148
20. Higazi A, Cohen R, Henkin J, Kniss D, Schwartz BS and Cines D (1995) Enhancement of the enzymatic activity of single chain urokinase plasminogen activator by soluble urokinase receptor. J Biol Chem 270: 17375-17380
21. Hollas W, Blasi F and Boyd D (1991) Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res 51: 3690-3695
22. Janknecht OR and Hunter T (1997) Activation of the Sap-1 a transcription factor by the c-Jun N-terminal kinase (JNK) mitogen-activated protein kinase. J Biol Chem 272: 4219-4224
23. Jankun J, Maher V and McCormick, J (1991) Malignant transformation of human fibroblasts correlates with increased activity of receptor-bound plasminogen activator. Cancer Res 51: 1221-1226
24. Kariko K, Kuo A, Boyd D, Okada S, Cines D and Barnathan E (1993) Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res 53: 3109-3117
25. Kook YH, Adamski J, Zelent A and Ossowski L (1994) The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. Eur Mol Biol Organ 13: 3983-3991
26. Lengyel E, Wang H, Gum R, Simon C, Wang Y and Boyd D (1997) Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-I-dependent signaling cascade. Oncogene 14: 2563-2573
27. Lengyel E, Wang H, Stepp E, Juarez J, Doc W, Pfarr CM and Boyd D (1996) Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J Biol Chem 271: 23176-23184
28. Lund L, Ronne E, Roldan A, Behrendt N, Romer J, Blasi F and Dano K (1991) Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells. J Biol 266: 5177-5181
29. Lund LR, Ellis V, Ronne E, Pyke C and Dano K (1995) Transcriptional and posttranscriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumor promoters in the human lung carcinoma cell line A549. Biochem J 310: 345-352
30. Lund LR, Ellis V, Ronne E, Pyke C and Dano K (1995) Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasmmogen activator by cytokines and tumor promoters in the human lung carcinoma cell line A549. Biochem J 310: 345-352
31. Mechta F, Lallemand D, Pfarr CM and Yaniv M (1997) Transformation by ras modifies AP1 composition and activity. Oncogene 14: 837-847
32. Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, Johnson GL and Karin M (1994a) Differential activation of ERK and JNK mitogen-activated protein kinases by raf-1 and MEKK. Science 266: 1719-1722
33. Minden A, Lin A, Smeal T, Derijard B, Cobb M, Davis R and Karin M (1994b) c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases. Mol Cell Biol 14: 6683-6688
34. Moller L, Pollanen J, Ronne E, Pedersen N and Blasi F (1993) N linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand. J Biol Chem 268: 11152-11159
35. Nead MA and McCance DJ (1995) Poly-L-ornithine-mediated transfection of human keratinocytes. J Invest Dermatol 105: 668-671
36. E1 expression, and spontaneous metastatic properties of rat mammary cells after transfection with c-Ha-ras or neo genes. Oncogene 5: 747-753
37. Nielsen L, Hansen J, Skriver L, Wilson E, Kaltoft K, Zenthen J and Dano K (1982) Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 21: 6410-6415
38. Nykjaer A, Conese M, Cremona O, Gliemann J and Blasi F (1997) Recycling of the urokinase receptor upon internalization of the uPA: serpin complexes. Eur Mol Biol Organ 16: 2610-2620
39. Ohmori M, Shirasawa S, Furuse M, Okumura K and Sasazuki T (1997) Activated Ki-ras enhances sensitivity of ceramide-induced apoptosis without c-Jun NH2-terminal kinase/stress-activated protein kinase or extracellular signal-regulated kinase activation in human colon cancer cells. Cancer Res 57: 4714-4717
40. Picone R, Kajtaniak E, Nielsen L, Behrendt N, Mastronicola M, Cubellis MV, Stoppelli MP, Pedersen S, Dano K and Blasi F (1989) Regulation of urokinase receptors in monocyte like cells U937 by phorbol ester phorhol myristate acetate. J Cell Biol 108: 693-702
41. Pyke C, Kristensen P, Ralfkiaer E, Grondahl-Hansen J, Eirksen J, Blasi F and Dano K (1991) Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059-1067
42. Pyke C, Eriksen J, Solberg H, Schnack B, Nielsen S, Kristensen P, Lund LR and Dano K (1993) An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator. FEBS 326: 69-74
43. Quatlrone A, Fibbi G, Anichini E, Pucci M, Zamperini A, Capaccioli S and Del Rosso M (1993) Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res 55: 90-95
44. Riittinen L, Limongi P, Crippa MP, Conese M, Hernandez-Marrero L, Fazioli F and Blasi F (1996) Removal of domain D2 or D3 of the human urokinase receptor does not affect ligand affinity. FEBS Lett 381: 1-6
45. Robbins KC, Summaria L, Hsieh B and Shah R (1967) The peptide chains of human plasmin. J Biol Chem 242: 2333-2342
46. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD and Downward J (1994) Phosphatidylinositol 3-OH kinase as a direct target of ras. Nature 370: 527-532
47. Roldan A, Cubellis M, Masucci M, Behrendt N, Lund L, Dano K, Appella E and Blasi F (1990) Cloning and expression of the receptor for urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. Eur Mol Biol Organ 9: 467-474
48. Russell M, Lange-Carter CA and Johnson GL (1995) Direct interaction between ras and the kinase domain of mitogen-activated protein kinase kinase (MEKK 1). J Biol Chem 270: 11757-11760
49. Schlechte W, Murano G and Boyd DD (1989) Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res 49: 6064 -6069
50. Shetty S, Kumar A and Idell S (1997) Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol Cell Biol 17: 1075-1083
51. Shirasawa S, Furusc M, Yokoyama N and Sasazuki T (1993) Altered growth of human colon cancer cell lines disrupted at activated, Ki-ras Science 260:85-88
52. Stoppelli MP, Tacchetti C, Cubellis M, Corti A, Hearing V, Cassani G, Appella E and Blasi F (1986) Autocrine saturation of pro-urakinase receptors on human A431 cells. Cell 45: 675-684
53. Vagnarelli P, Raimondi E, Mazzicri R, De Carli L and Migantti P (1992) Assignment of the human urokinase receptor gene (PLAU) to 19q13. Cytogenet Cell Genet 60: 197-199
54. Vassalli J, Baccino D and Belin D (1985) A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100: 86-92
55. Wang Y, Dang J, Johnson LK, Selhamer JJ and Doe WF (1995) Structure of the human urokinase receptor gene and its similarity to CD59 and the Ly-6 family. Eur J Biochem 227: 116-122
56. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV and Chapman HA (1996) Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555
57. Wilhelm O, Weilde U, Rettenberger S, Schmitt M and Graeff H (1994) Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhihition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 337: 131-134
58. Winkler DG, Johnson JC, Cooper JA and Vojtek AB (1997) Identification and characterization of mutations in Ha-Ras that selectively decrease binding to cRaf-1. J Biol Chem 272: 24402-24409
59. Yebra M, Parry GCN, Stromblad S, Mackman N, Rosenberg S, Mueller BM and Cheresh DA (1996) Requirement of receptor-bound urokinase-type plasminogen activator for integrin αvβ 5-directed cell migration. J Biol Chem 271: 29393-29399